CA Patent

CA2303752A1 — Renal cell carcinoma treatment

Assigned to Merck Sharp and Dohme LLC · Expires 2000-10-08 · 26y expired

What this patent protects

Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g. , pegylated interferon alfa-2b as monotherapy or in…

USPTO Abstract

Methods for treating treatment-naive as well as treatment-experienced patients having RCC to achieve at least a partial tumor response involving administering a therapeutically effective amount of pegylated interferon-alfa, e.g. , pegylated interferon alfa-2b as monotherapy or in association with a therapeutically effective amount of IL-2 are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA2303752A1
Jurisdiction
CA
Classification
—
Expires
2000-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Merck Sharp and Dohme LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.